Daniel W Chan

发表

Recommendations for Mass Spectrometry Data Quality Metrics for Open Access Data (Corollary to the Amsterdam Principles)*

Richard D Smith, Mark Baker, John R Yates, 2011, Molecular & Cellular Proteomics.

Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

William E Grizzle, William Rom, Daniel W Chan, 2009, Journal of proteome research.

Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles).

Richard D Smith, Mark Baker, John R Yates, 2012, Journal of proteome research.

Updating risk prediction tools: A case study in prostate cancer

Yuanyuan Liang, Ziding Feng, Daniel W Chan, 2012, Biometrical journal. Biometrische Zeitschrift.

Exciting news from Clinical Proteomics

Daniel W Chan, 2011, Clinical Proteomics.

Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles)

Richard D Smith, John R Yates, Henning Hermjakob, 2011, Proteomics. Clinical applications.

Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

Yair Lotan, Sudhir Srivastava, Ziding Feng, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides

Paul Aiyetan, Hui Zhang, Daniel W Chan, 2016, Nature Biotechnology.

Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI).

Daniel W Chan, Robert W Veltri, Alan W Partin, 2003, Reviews in urology.

Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.

Lori J Sokoll, Hui Zhang, Daniel W Chan, 2009, Journal of proteome research.

The clinical application of proteomics.

Daniel W Chan, D. Chan, David A Colantonio, 2005, Clinica chimica acta; international journal of clinical chemistry.

Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?

Lori J Sokoll, Daniel W Chan, Alan W Partin, 2016, The Journal of urology.

Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization‐time of flight (SELDI‐TOF) mass spectrometry: Multi‐institution correlation of spectra and identification of biomarkers

O John Semmes, Daniel W Chan, Bao-Ling Adam, 2005, Proteomics.

Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population.

Daniel W Chan, Alan W Partin, D. Chan, 2004, The Journal of urology.

Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay.

Lori J Sokoll, Daniel W Chan, Yee Chan-Li, 2006, Clinical chemistry.

Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels*

Ronald J Moore, Vladislav A Petyuk, Feng Yang, 2014, Molecular & Cellular Proteomics.

Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.

Lori J Sokoll, Daniel W Chan, Alan W Partin, 2009, The Journal of urology.

Classification of cancer types by measuring variants of host response proteins using SELDI serum assays

Xiao-Ying Meng, Zheng Wang, Daniel W Chan, 2005, International journal of cancer.

Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Daniel W Chan, D. Chan, I. Shih, 2009, Neoplasia.

The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.

Ziding Feng, Daniel W Chan, Donna P Ankerst, 2013, The Journal of urology.

The human proteome – a scientific opportunity for transforming diagnostics, therapeutics, and healthcare

Mark Gerstein, Marc Vidal, Matthias Mann, 2012, Clinical Proteomics.

Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry.

Xiao-Ying Meng, Daniel W Chan, Jing Zhao, 2005, Clinical chemistry.

Cancer Proteomics: Serum Diagnostics for Tumor Marker Discovery

Daniel W Chan, D. Chan, A. Rai, 2004, Annals of the New York Academy of Sciences.

Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

Daniel W Chan, Yinhua Yu, R. Bast, 2007, Gynecologic oncology.

Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.

Lori J Sokoll, Hsueh-Wei Chang, Daniel W Chan, 2003, Journal of the National Cancer Institute.

Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays.

Michael J MacCoss, Jing Chen, Brendan MacLean, 2016, Methods in molecular biology.

Cancer Biomarker Discovery in Plasma Using a Tissue-targeted Proteomic Approach

Hui Zhang, Daniel W Chan, D. Chan, 2007, Cancer Epidemiology Biomarkers & Prevention.

Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues.

Chen, Li, Christopher R Kinsinger, 2017, Journal of proteome research.